Format

Send to

Choose Destination

Links from PubMed

See comment in PubMed Commons below
J Stroke Cerebrovasc Dis. 2010 Jan;19(1):3-9. doi: 10.1016/j.jstrokecerebrovasdis.2009.09.005.

Intranasal administration of PEGylated transforming growth factor-alpha improves behavioral deficits in a chronic stroke model.

Author information

1
Department of Anatomy and Neurobiology, University of California Irvine, Irvine, California 92697, USA. magdagmx@hotmail.com

Abstract

We previously demonstrated that infusion of transforming growth factor (TGF)-alpha after chronic middle cerebral artery occlusion (MCAO) stimulates stem and progenitor cell proliferation, migration, and neuronal differentiation associated with the amelioration of neurologic impairment. But the use of TGF-alpha in humans is impeded by impracticality of intracranial infusion and the inability of intravenous TGF-alpha to cross the blood-brain barrier. Here we investigated whether intranasal delivery of PEGylated TGF-alpha (PEG-TGF-alpha) is a viable alternative. We found that intranasal PEG-TGF-alpha can also induce the proliferation of neural progenitors and their migration to the damaged striatum, and that this is associated with significant behavioral improvement in the MCAO model. This nonsurgical approach represents a potential therapeutic strategy for human patients.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center